Work

A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.

Year: 2009

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs-09-3094

Authors: I. Mayer, J. Means-Powell, Y. Shyr, C. Arteaga

Institution: Vanderbilt-Ingram Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2067996026

Cites:

Cited by: 6

Related to: 10